[{"id":"6dc76f3c-ed63-4771-a0a4-3ac73d6fddbc","acronym":"ELEVATE-TN","url":"https://clinicaltrials.gov/study/NCT02475681","created_at":"2021-01-17T17:35:21.456Z","updated_at":"2024-07-02T16:35:00.298Z","phase":"Phase 3","brief_title":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL","source_id_and_acronym":"NCT02475681 - ELEVATE-TN","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD20 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib) • Leukeran (chlorambucil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 535","initiation":"Initiation: 06/26/2015","start_date":" 06/26/2015","primary_txt":" Primary completion: 02/08/2019","primary_completion_date":" 02/08/2019","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-29"},{"id":"e81c8424-a296-48d7-a4d2-c6f1231c20b0","acronym":"SALE","url":"https://clinicaltrials.gov/study/NCT04692740","created_at":"2021-01-19T20:48:58.009Z","updated_at":"2024-07-02T16:35:36.241Z","phase":"Phase 2","brief_title":"Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)","source_id_and_acronym":"NCT04692740 - SALE","lead_sponsor":"Michele Reni","biomarkers":" BRCA1 • BRCA2 • HRD","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation","tags":["BRCA1 • BRCA2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukeran (chlorambucil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 01/04/2023","primary_completion_date":" 01/04/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-09-21"},{"id":"2f7674d9-be91-409b-a78a-efea8c41ee23","acronym":"","url":"https://clinicaltrials.gov/study/NCT01808599","created_at":"2021-01-18T08:01:12.475Z","updated_at":"2024-07-02T16:35:47.649Z","phase":"Phase 2","brief_title":"Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma","source_id_and_acronym":"NCT01808599","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukeran (chlorambucil) • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2023-05-18"},{"id":"49626a4e-593f-485a-8606-590478c6b460","acronym":"GAIRI","url":"https://clinicaltrials.gov/study/NCT03529227","created_at":"2021-01-18T17:22:31.653Z","updated_at":"2024-07-02T16:36:17.169Z","phase":"","brief_title":"Gazyva Infusion Reaction Investigation","source_id_and_acronym":"NCT03529227 - GAIRI","lead_sponsor":"Healthy Future","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Leukeran (chlorambucil)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 03/31/2018","start_date":" 03/31/2018","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2022-02-14"},{"id":"43cc2176-b27f-4bca-b397-b12e19417b2d","acronym":"iLLUMINATE ","url":"https://clinicaltrials.gov/study/NCT02264574","created_at":"2021-01-17T17:35:09.358Z","updated_at":"2024-07-02T16:36:40.852Z","phase":"Phase 3","brief_title":"A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT02264574 - iLLUMINATE ","lead_sponsor":"Pharmacyclics LLC.","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p) • IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Leukeran (chlorambucil)"],"overall_status":"Completed","enrollment":" Enrollment 229","initiation":"Initiation: 10/06/2014","start_date":" 10/06/2014","primary_txt":" Primary completion: 03/26/2018","primary_completion_date":" 03/26/2018","study_txt":" Completion: 09/03/2019","study_completion_date":" 09/03/2019","last_update_posted":"2020-09-21"},{"id":"fb9c1e87-d169-44ca-99f2-f7683ca34b54","acronym":"","url":"https://clinicaltrials.gov/study/NCT01905943","created_at":"2021-01-18T08:35:06.441Z","updated_at":"2024-07-02T16:36:54.188Z","phase":"Phase 3","brief_title":"A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01905943","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • cyclophosphamide • bendamustine • Leukeran (chlorambucil) • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 979","initiation":"Initiation: 11/04/2013","start_date":" 11/04/2013","primary_txt":" Primary completion: 12/29/2016","primary_completion_date":" 12/29/2016","study_txt":" Completion: 10/08/2018","study_completion_date":" 10/08/2018","last_update_posted":"2019-10-28"},{"id":"b8f3f999-915e-4116-93f2-ac668d940320","acronym":"","url":"https://clinicaltrials.gov/study/NCT00210353","created_at":"2021-01-18T00:42:53.803Z","updated_at":"2024-07-02T16:36:59.031Z","phase":"Phase 3","brief_title":"Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma","source_id_and_acronym":"NCT00210353","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Leukeran (chlorambucil)"],"overall_status":"Completed","enrollment":" Enrollment 454","initiation":"Initiation: 01/01/2003","start_date":" 01/01/2003","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 02/17/2016","study_completion_date":" 02/17/2016","last_update_posted":"2019-06-06"}]